Casertano Marianna, Trotta Maria Consiglia, Cenni Sabrina, Creoli Mara, Miele Erasmo, Martinelli Massimo, Lepre Caterina Claudia, Russo Marina, Alfano Roberto, D'Amico Michele, Strisciuglio Caterina
Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Acta Paediatr. 2024 Mar;113(3):590-597. doi: 10.1111/apa.17072. Epub 2023 Dec 23.
We aimed to evaluate the serum and faecal expression of miR-126 and miR-20a in children with Crohn's disease (CD) during infliximab (IFX) therapy.
In this prospective observational study, serum and faeces from CD patients were collected before IFX therapy (T0), after induction (T1) and after 6 months from IFX (T2). IFX levels were determined by Enzyme-linked immunosorbent assay at T1 and T2. miRNAs were profiled through Real-Time RT-PCR. The activity of disease was evaluated through the Paediatric Crohn's disease activity index (PCDAI), serum C-reactive protein (CRP) and faecal calprotectin.
Nine CD children were enrolled. Serum and faecal miR-126 and miR-20a levels were higher at T0 and showed a time-dependent decrease, being significantly down-regulated after IFX treatment at T2. Specifically, IFX levels recorded at T1 and T2 negatively correlated with the serum and faecal expression of miR-126 and miR-20a. Serum and faecal changes of miR-126 and miR20-a were positively associated with the decrease of the inflammatory marker CRP and PDCAI at all time points.
In children with CD, IFX therapy decreases the expression of serum and faecal miR-126 and miR-20a, suggesting an involvement of these two miRNAs in the action of the drug.
我们旨在评估英夫利昔单抗（IFX）治疗期间克罗恩病（CD）患儿血清和粪便中miR-126和miR-20a的表达情况。
在这项前瞻性观察研究中，收集CD患者在IFX治疗前（T0）、诱导治疗后（T1）以及IFX治疗6个月后（T2）的血清和粪便样本。在T1和T2时通过酶联免疫吸附测定法测定IFX水平。通过实时逆转录聚合酶链反应分析miRNA。通过儿童克罗恩病活动指数（PCDAI）、血清C反应蛋白（CRP）和粪便钙卫蛋白评估疾病活动度。
纳入9名CD患儿。血清和粪便中miR-126和miR-20a水平在T0时较高，并呈现出时间依赖性下降，在T2接受IFX治疗后显著下调。具体而言，T1和T2时记录的IFX水平与miR-126和miR-20a的血清和粪便表达呈负相关。在所有时间点，miR-126和miR-20a的血清和粪便变化与炎症标志物CRP和PDCAI的降低呈正相关。
在CD患儿中，IFX治疗可降低血清和粪便中miR-126和miR-20a的表达，提示这两种miRNA参与了该药物的作用机制。
